Impact of National Covid-19 Vaccination Campaign, South Korea

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2022 May 15

PMID 35570077

Authors

Seonju Yi

Young June Choe

Do Sang Lim

Hye Roen Lee

Jia Kim

Yoo-Yeon Kim

Ryu Kyung Kim

Eun Jung Jang

Sangwon Lee

Eunjoo Park

Seung-Jin Kim

Young-Joon Park

Affiliations

Soon will be listed here.

Abstract

Background: We evaluate the overall effectiveness of the nationwide vaccination campaign using ChAdOx1 nCoV-19, BNT162b2, mRNA-1273, and Ad26.COV2.S vaccines in preventing Covid-19 in South Korea.

Methods: The National Surveillance System with the National Immunization Registry were linked to form a large-linked database for assessment. Age-adjusted incidence of SARS-CoV-2 infection, severe disease, and death by vaccination status are calculated. Weekly vaccine effectiveness was calculated based on incidence rate ratio (IRR) between fully-vaccinated and unvaccinated persons, as: IRR = incidence rate of vaccinated / incidence rate of unvaccinated. We estimate the cumulative SARS-CoV-2 outcome overtime comparing the observed case with predicted cases without vaccination.

Results: Age-adjusted incidence in unvaccinated persons (5.69 per 100,000 person-day) was 2.7 times the rate in fully vaccinated (2.13 per 100,000 person-day) persons, resulting effectiveness against SARS-CoV-2 infection of 63%. Vaccine effectiveness against severe disease and death were 93% and 95%, respectively. Between March and October 2021, estimated Covid-19 related outcomes averted by vaccinations were: 46,508 infections, 3,424 severe diseases, and 718 deaths.

Conclusions: We found significant protection for national Covid-19 vaccination campaign against Covid-19 severe disease, and death in target populations, but there was an unexpected decreased protection against SARS-CoV-2 infection, highlighting the importance of continued surveillance and assessment.

Citing Articles

Analyzing COVID-19 progression with Markov multistage models: insights from a Korean cohort.

Ndagijimana F, Park T Genomics Inform. 2025; 23(1):2.

PMID: 39891219 PMC: 11786383. DOI: 10.1186/s44342-024-00035-y.

Modeling COVID-19 dynamics in the Basque Country: characterizing population immunity profile from 2020 to 2022.

Naffeti B, Ounissi Z, Srivastav A, Stollenwerk N, Van-Dierdonck J, Aguiar M BMC Infect Dis. 2025; 25(1):9.

PMID: 39748283 PMC: 11697651. DOI: 10.1186/s12879-024-10342-y.

Effectiveness of the Bivalent mRNA COVID-19 Vaccine for Preventing Critical Infection From the SARS-CoV-2 Omicron Variant in the Republic of Korea.

Choi Y, Ryu S, Kim R, Chiara A, Baek S, Nam H J Korean Med Sci. 2024; 39(37):e258.

PMID: 39355951 PMC: 11444818. DOI: 10.3346/jkms.2024.39.e258.

Worsening of health disparities across COVID-19 pandemic stages in Korea.

Lee H, Nam H, Lee J, Jung H, Lee J Epidemiol Health. 2024; 46:e2024038.

PMID: 38514197 PMC: 11176714. DOI: 10.4178/epih.e2024038.

Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.

Kim R, Choe Y, Jang E, Chae C, Hwang J, Lee K J Korean Med Sci. 2023; 38(46):e396.

PMID: 38013649 PMC: 10681846. DOI: 10.3346/jkms.2023.38.e396.

References

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

Sheikh A, Robertson C, Taylor B . BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. N Engl J Med. 2021; 385(23):2195-2197. PMC: 8552534. DOI: 10.1056/NEJMc2113864. View

Lee J . How to deal with the Delta variant this fall. Osong Public Health Res Perspect. 2021; 12(4):201-202. PMC: 8408416. DOI: 10.24171/j.phrp.2021.0217. View

Choi M, Choi W, Seong H, Choi J, Kim J, Kim Y . Developing a Framework for Pandemic COVID-19 Vaccine Allocation: a Modified Delphi Consensus Study in Korea. J Korean Med Sci. 2021; 36(23):e166. PMC: 8203851. DOI: 10.3346/jkms.2021.36.e166. View

Pouwels K, Pritchard E, Matthews P, Stoesser N, Eyre D, Vihta K . Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021; 27(12):2127-2135. PMC: 8674129. DOI: 10.1038/s41591-021-01548-7. View

Min K, Tak S . Dynamics of the COVID-19 epidemic in the post-vaccination period in Korea: a rapid assessment. Epidemiol Health. 2021; 43:e2021040. PMC: 8289478. DOI: 10.4178/epih.e2021040. View

Cohn B, Cirillo P, Murphy C, Krigbaum N, Wallace A . SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2021; 375(6578):331-336. PMC: 9836205. DOI: 10.1126/science.abm0620. View

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View

Fiolet T, Kherabi Y, MacDonald C, Ghosn J, Peiffer-Smadja N . Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2021; 28(2):202-221. PMC: 8548286. DOI: 10.1016/j.cmi.2021.10.005. View

10.

Haas E, Angulo F, McLaughlin J, Anis E, Singer S, Khan F . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397(10287):1819-1829. PMC: 8099315. DOI: 10.1016/S0140-6736(21)00947-8. View

11.

Tang P, Hasan M, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021; 27(12):2136-2143. DOI: 10.1038/s41591-021-01583-4. View

12.

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

13.

Kennedy D, Vu V, Ritchie H, Bartlein R, Rothschild O, Bausch D . COVID-19: Identifying countries with indicators of success in responding to the outbreak. Gates Open Res. 2021; 4:62. PMC: 8515014. DOI: 10.12688/gatesopenres.13140.2. View

14.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

15.

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021; 385(15):1393-1400. PMC: 8461568. DOI: 10.1056/NEJMoa2114255. View

16.

Iacobucci G . Covid-19: How is the UK's vaccine booster programme faring?. BMJ. 2021; 375:n2702. DOI: 10.1136/bmj.n2702. View